The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice

Medicin og biovidenskab

• 130-nm albumin-bound paclitaxel 20%
• atezolizumab 20%
• Biomarkers 51%
• Breast Neoplasms 50%
• Clinical Trials 51%
• Eosine Yellowish-(YS) 13%
• Hematoxylin 13%
• Ireland 14%
• Neoplasms 8%
• Pathology 16%
• Patient Selection 34%
• Risk Management 86%
• Standard of Care 12%
• Survival 7%
• Therapeutics 6%
• Triple Negative Breast Neoplasms 47%
• Tumor-Infiltrating Lymphocytes 100%